Stay updated with breaking news from Solid Tumor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Biomunex Pharmaceuticals, a French company focused on the discovery and development of bi- and multi-specific antibodies, sees its BiXAb5 project receive nearly €3m (US$3.5m) in the form of a grant from the French government.
A University of Pennsylvania team has developed a new type of engineered immune cell called “peptide-centric” CAR-T that's designed to shrink solid tumors by targeting proteins inside cancer cells. CAR-T cells developed with the technology eradicated neuroblastoma in mouse models and could move into human trials in 2022 or 2023.
/PRNewswire/ -- DelveInsight's Bone Metastasis in Solid Tumors Market Insights report proffers a detailed comprehension of Bone Metastasis in Solid Tumors...
Yale University spinout Cybrexa Therapeutics has developed a peptide-drug conjugate that, instead of aiming for a specific antigen, targets the acidic environment of cancer cells to deliver a toxic payload. The drug improved the efficacy of checkpoint inhibitors in mouse models of cancer.
Jun 3, 2021 8:40am The setback has led to the winding down of the CART-PSMA-TGFβRDN study. (Image by Dimitris Vetsikas from Pixabay) Tmunity Therapeutics has stopped development of its lead CAR-T therapy after two patients died of a form of neurotoxicity. The news, details of which were first reported by Endpoints, has implications for the broader push to establish cell therapies as treatments for solid tumors. Founded by Carl June, M.D., and Oz Azam, M.D., Tmunity is at the forefront of the push to expand use of CAR-T beyond hematological malignancies and into solid tumors. The Un...